TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors
TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors is a paper indexed in PICO Portal from OpenAlex.
How many citations does TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors have?
TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors has 0 citations in the OpenAlex counts PICO Portal stores.
When was TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors published?
TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors has 2026 year in the PICO Portal index.
What is the open-access status of TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors?
TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors has green oa status in the PICO Portal index.
What is the DOI of TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors?
The DOI for TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors is on the source record.
What is the OpenAlex record for TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors?
The OpenAlex for TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors is on the source record.